This topic contains 0 replies, has 1 voice, and was last updated by  MS News Today Moderator 3 weeks, 3 days ago.

  • Author
    Posts
  • #18473
     MS News Today Moderator 
    Participant

    Long-term treatment with Gilenya (fingolimod) in patients with relapsing forms of multiple sclerosis (MS) is safe and effective, a Phase 3 trial shows. Read more about it here.

    Have you heard of this news? What are your thoughts about these results?

You must be logged in to reply to this topic.

Copyright © 2017-2019 All rights reserved.

©2019 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending
or

Log in with your credentials

or    

Forgot your details?

or

Create Account